vimarsana.com

தேசிய ப்ரிஸ்க்ரிப்ஶந் தணிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ACC: Analyses Find SGLT2i Therapy Effective But Underutilized

May 19, 2021 Current guidelines strongly recommend use of the therapy for cardiology, diabetes patients In a series of presentations at ACC.21, the virtual meeting of the American College of Cardiology, researchers delivered data to confirm two observations about cardiovascular outcomes in heart failure patients with or without type 2 diabetes (T2D) and/or chronic kidney disease (CDK). First, the use of SGLT2 inhibitors is associated with reduced risk of cardiovascular death, worsening heart failure, and/or hospitalization for heart failure, and second, SGLT2i agents are woefully underused. In a presentation titled, “Just Go With the Flo(zin): SGLT2i Should Be Added to A Few, Some, Most, All HFrEF Patients?”, Glenn Herrington, PharmD, Ambulatory Care Cardiology Pharmacist at New Hanover Regional Medical Center in Wilmington, North Carolina, reviewed findings from EMPA-REG OUTCOME, CANVAS PROGRAM,DECLARE-TIMI 58, VERTIS CV, DAPA-HF, and EMPEROR-REDUCED to assess benefits and

News Scan for Dec 22, 2020

A study in JAMA Internal Medicine today demonstrates a sharp decline in US hospital COVID-19 mortality rates during the first 6 months of the pandemic, with wide variation across hospitals and poorer outcomes linked to higher county-level case rates.   Researchers compared outcomes for 38,517 adult COVID-19 patients admitted to 955 US hospitals during an early (Jan 1 to Apr 30) and late (from May 1 to Jun 30) pandemic period. They estimated each hospital s risk-standardized event rate (RSER), which is a measure of average patient risk of 30-day in-hospital mortality or referral to hospice. The overall mean RSER for 955 hospitals was 11.8%, with a range from 9.1% to 15.7% for the best- and worst-performing hospital quintiles (absolute difference 6.59 percentage points; 95% confidence interval [CI], 6.4% to 6.8%;

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.